JP2008516973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516973A5 JP2008516973A5 JP2007536949A JP2007536949A JP2008516973A5 JP 2008516973 A5 JP2008516973 A5 JP 2008516973A5 JP 2007536949 A JP2007536949 A JP 2007536949A JP 2007536949 A JP2007536949 A JP 2007536949A JP 2008516973 A5 JP2008516973 A5 JP 2008516973A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- methyl
- imidazo
- pyrimidin
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 3- (Ethylsulfonyl) phenyl Chemical group 0.000 claims description 846
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 211
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 claims description 174
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims description 70
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 56
- BOUIZPWBFIVJPD-UHFFFAOYSA-N 3h-1,2,4-triazin-4-amine Chemical class NN1CN=NC=C1 BOUIZPWBFIVJPD-UHFFFAOYSA-N 0.000 claims description 31
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 20
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 16
- 150000001408 amides Chemical class 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 12
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims description 10
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 claims description 6
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims description 6
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 claims description 4
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 claims description 4
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims description 4
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 4
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- QVESPAZTKUYKFE-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC=3NN=C(C)C=3)N3C=CN=C3C=2)=C1 QVESPAZTKUYKFE-UHFFFAOYSA-N 0.000 claims description 4
- MTEVLMIUCCLOJF-UHFFFAOYSA-N 7-[3-(ethylsulfonylmethyl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)CC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 MTEVLMIUCCLOJF-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 4
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 4
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 4
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 4
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 4
- ZFCHNZDUMIOWFV-UHFFFAOYSA-M pyrimidine-2-carboxylate Chemical compound [O-]C(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-M 0.000 claims description 4
- HMKSATPFCVLZAD-KRWDZBQOSA-N (2s)-n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]oxolane-2-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)[C@H]3OCCC3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 HMKSATPFCVLZAD-KRWDZBQOSA-N 0.000 claims description 2
- CMDUDMQXEVARHF-KRWDZBQOSA-N (2s)-n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)[C@H]3NCCC3)C=CC=2)=N1 CMDUDMQXEVARHF-KRWDZBQOSA-N 0.000 claims description 2
- FYLXOUQHGOJJRI-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanone Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(C=CC=2)C(=O)N2CCC(O)CC2)=N1 FYLXOUQHGOJJRI-UHFFFAOYSA-N 0.000 claims description 2
- OTBFUMSMIVYLAK-UHFFFAOYSA-N 1,3-thiazole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CS1 OTBFUMSMIVYLAK-UHFFFAOYSA-N 0.000 claims description 2
- AFCXECFLGWINNG-UHFFFAOYSA-N 1-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]imidazolidin-2-one Chemical compound O=C1NCCN1CC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 AFCXECFLGWINNG-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- ZZPZQIMGCDVBIX-UHFFFAOYSA-N 2-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]-n-phenylacetamide Chemical compound N=1C(C2=CN(CC(=O)NC=3C=CC=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 ZZPZQIMGCDVBIX-UHFFFAOYSA-N 0.000 claims description 2
- DYADDGIMLGZAON-UHFFFAOYSA-N 2-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C(=CC=CC=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 DYADDGIMLGZAON-UHFFFAOYSA-N 0.000 claims description 2
- BJQRCMRGLKTFCX-UHFFFAOYSA-N 2-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C(=CC=CC=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 BJQRCMRGLKTFCX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- FMMUQXDMPOTDLB-UHFFFAOYSA-N 2-methyl-7-[1-(2-methylpropyl)pyrazol-4-yl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class C1=NN(CC(C)C)C=C1C1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 FMMUQXDMPOTDLB-UHFFFAOYSA-N 0.000 claims description 2
- NWUUBYBANOEWNL-UHFFFAOYSA-N 2-methyl-7-[3-(3-methylimidazol-4-yl)phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C=2N(C=NC=2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 NWUUBYBANOEWNL-UHFFFAOYSA-N 0.000 claims description 2
- NMSNGWOXZGUXPU-UHFFFAOYSA-N 2-methyl-7-[3-[3-(methylamino)pyrrolidin-1-yl]sulfonylphenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1C(NC)CCN1S(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 NMSNGWOXZGUXPU-UHFFFAOYSA-N 0.000 claims description 2
- QHCODFQJYAZFBH-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-piperazin-1-ylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)N2CCNCC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 QHCODFQJYAZFBH-UHFFFAOYSA-N 0.000 claims description 2
- HUPVQHYRVNCWRU-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-propan-2-yloxyphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CC(C)OC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 HUPVQHYRVNCWRU-UHFFFAOYSA-N 0.000 claims description 2
- RWXSVGBXJSUDBT-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-propoxyphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCCOC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 RWXSVGBXJSUDBT-UHFFFAOYSA-N 0.000 claims description 2
- OAZQHPZMYBNBIE-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-(3-pyrrolidin-1-ylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)N2CCCC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 OAZQHPZMYBNBIE-UHFFFAOYSA-N 0.000 claims description 2
- QMETZUFLUYJPNN-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[1-(1-phenylpropan-2-yl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=NN1C(C)CC1=CC=CC=C1 QMETZUFLUYJPNN-UHFFFAOYSA-N 0.000 claims description 2
- WJXWUUGUOWMEAY-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[1-(2-piperidin-1-ylethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CCN3CCCCC3)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 WJXWUUGUOWMEAY-UHFFFAOYSA-N 0.000 claims description 2
- WGMYRTALXBVWPI-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[1-[[2-(trifluoromethoxy)phenyl]methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C(=CC=CC=3)OC(F)(F)F)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 WGMYRTALXBVWPI-UHFFFAOYSA-N 0.000 claims description 2
- HCPAPPQGSRCYQN-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(1,3,5-trimethylpyrazol-4-yl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(N(C)N=C2C)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 HCPAPPQGSRCYQN-UHFFFAOYSA-N 0.000 claims description 2
- UVPZIMVFHCTSED-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(1,3-thiazol-2-ylsulfonyl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical class N=1C(C=2C=C(C=CC=2)S(=O)(=O)C=2SC=CN=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 UVPZIMVFHCTSED-UHFFFAOYSA-N 0.000 claims description 2
- GGVKDZOKPSTLDC-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(1h-pyrrolo[2,3-b]pyridin-4-yl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C=2C=3C=CNC=3N=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 GGVKDZOKPSTLDC-UHFFFAOYSA-N 0.000 claims description 2
- SJXFROBNJHRXJZ-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(3-methylpyridin-4-yl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C=2C(=CN=CC=2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 SJXFROBNJHRXJZ-UHFFFAOYSA-N 0.000 claims description 2
- CFVGGCMTRZKEGF-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(piperazin-1-ylmethyl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(CN3CCNCC3)C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 CFVGGCMTRZKEGF-UHFFFAOYSA-N 0.000 claims description 2
- LJWJMBSFNXRTKZ-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-(piperidin-1-ylmethyl)phenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(CN3CCCCC3)C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 LJWJMBSFNXRTKZ-UHFFFAOYSA-N 0.000 claims description 2
- UZYXIAWQWYJODS-KRWDZBQOSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-[3-[(3s)-pyrrolidin-3-yl]sulfonylphenyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)[C@@H]2CNCC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 UZYXIAWQWYJODS-KRWDZBQOSA-N 0.000 claims description 2
- OLTXWOKQKOFPJB-UHFFFAOYSA-N 2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-7-phenyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C)CN2C=1C=C(C=1C=CC=CC=1)N=C2NC=1C=C(C)NN=1 OLTXWOKQKOFPJB-UHFFFAOYSA-N 0.000 claims description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- JBJDYLNJACPLLX-UHFFFAOYSA-N 3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-n-phenylbenzenesulfonamide Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)NC=2C=CC=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 JBJDYLNJACPLLX-UHFFFAOYSA-N 0.000 claims description 2
- YVJWNCMKNALEFQ-UHFFFAOYSA-N 3-[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]propanoic acid Chemical compound N=1C(C=2C=C(CCC(O)=O)C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 YVJWNCMKNALEFQ-UHFFFAOYSA-N 0.000 claims description 2
- DVFMQGYTPGZVKT-UHFFFAOYSA-N 3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]-2-(trifluoromethyl)imidazo[1,2-c]pyrimidin-7-yl]-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(N=C3C=2)C(F)(F)F)=C1 DVFMQGYTPGZVKT-UHFFFAOYSA-N 0.000 claims description 2
- LPPRBBIYICZEFR-UHFFFAOYSA-N 3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-n-phenylbenzamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(C=CC=2)C(=O)NC=2C=CC=CC=2)=N1 LPPRBBIYICZEFR-UHFFFAOYSA-N 0.000 claims description 2
- ORCOODHIVUUVOE-UHFFFAOYSA-N 3-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]imidazolidine-2,4-dione Chemical compound O=C1CNC(=O)N1CC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 ORCOODHIVUUVOE-UHFFFAOYSA-N 0.000 claims description 2
- DLEFVSSWSFGQPX-UHFFFAOYSA-N 3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]-n-(1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)C(=O)NC=3SC=CN=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 DLEFVSSWSFGQPX-UHFFFAOYSA-N 0.000 claims description 2
- BLNSBTUIAOGZLD-UHFFFAOYSA-N 3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 BLNSBTUIAOGZLD-UHFFFAOYSA-N 0.000 claims description 2
- JPOQCJAAIXGTBI-UHFFFAOYSA-N 3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 JPOQCJAAIXGTBI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims description 2
- FVKMTLTURWXMMO-UHFFFAOYSA-N 4-fluoro-2-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzonitrile Chemical compound N=1C(C2=CN(CC=3C(=CC=C(F)C=3)C#N)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 FVKMTLTURWXMMO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- SDAQUGZAOYECMS-UHFFFAOYSA-N 4-methyl-5-[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]-1,3-thiazol-2-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(N=C(N)S2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 SDAQUGZAOYECMS-UHFFFAOYSA-N 0.000 claims description 2
- JQTMGOLZSBTZMS-UHFFFAOYSA-N 4-methylpiperazine-1-carbaldehyde Chemical compound CN1CCN(C=O)CC1 JQTMGOLZSBTZMS-UHFFFAOYSA-N 0.000 claims description 2
- JMRCUGIJPUHNTG-UHFFFAOYSA-N 5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound N=1C(C=2C=C3NC(=O)NC3=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 JMRCUGIJPUHNTG-UHFFFAOYSA-N 0.000 claims description 2
- MVSDXNWHSCXNAS-UHFFFAOYSA-N 7-(1-benzylpyrazol-4-yl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class N=1C(C2=CN(CC=3C=CC=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 MVSDXNWHSCXNAS-UHFFFAOYSA-N 0.000 claims description 2
- HKECOZMPQMRCJK-UHFFFAOYSA-N 7-(1h-indol-4-yl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=3C=CNC=3C=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 HKECOZMPQMRCJK-UHFFFAOYSA-N 0.000 claims description 2
- LTPSVIBVXJWVQT-UHFFFAOYSA-N 7-(2-aminophenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C(=CC=CC=2)N)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 LTPSVIBVXJWVQT-UHFFFAOYSA-N 0.000 claims description 2
- UGCNIQVBHFPXNJ-UHFFFAOYSA-N 7-(3-ethylsulfanylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCSC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 UGCNIQVBHFPXNJ-UHFFFAOYSA-N 0.000 claims description 2
- JOTRISSZVLESNJ-UHFFFAOYSA-N 7-(3-ethylsulfinylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 JOTRISSZVLESNJ-UHFFFAOYSA-N 0.000 claims description 2
- GHHGEXOQPOBCPJ-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-2-(imidazol-1-ylmethyl)-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(CN4C=NC=C4)N=C3C=2)=C1 GHHGEXOQPOBCPJ-UHFFFAOYSA-N 0.000 claims description 2
- OFRHKIQDPFRXSH-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-2-[(4-methylpiperazin-1-yl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(CN4CCN(C)CC4)N=C3C=2)=C1 OFRHKIQDPFRXSH-UHFFFAOYSA-N 0.000 claims description 2
- YVLCDISVYKDXJC-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 YVLCDISVYKDXJC-UHFFFAOYSA-N 0.000 claims description 2
- JVNZYHOPDGUBTK-UHFFFAOYSA-N 7-(3-ethylsulfonylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3N=CN=C3C=2)=C1 JVNZYHOPDGUBTK-UHFFFAOYSA-N 0.000 claims description 2
- OMHDEXPHTJYNEI-UHFFFAOYSA-N 7-(4-methoxy-3-morpholin-4-ylsulfonylphenyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=C1S(=O)(=O)N1CCOCC1 OMHDEXPHTJYNEI-UHFFFAOYSA-N 0.000 claims description 2
- CFHDCDMYZFTSAV-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CN(C)CCN1C1=CC2=NC=CN2C(NC2=NNC(C)=C2)=N1 CFHDCDMYZFTSAV-UHFFFAOYSA-N 0.000 claims description 2
- ROWMGPCTWSWMLA-UHFFFAOYSA-N 7-[(2-methoxyphenyl)methyl]-5-N-(5-methyl-1H-pyrazol-3-yl)-3H-imidazo[1,2-c]pyrimidine-5,7-diamine Chemical compound COC1=C(CC2(C=C3N(C(=N2)NC2=NNC(=C2)C)CC=N3)N)C=CC=C1 ROWMGPCTWSWMLA-UHFFFAOYSA-N 0.000 claims description 2
- DFBVARVABSDNCV-UHFFFAOYSA-N 7-[1-(2,1,3-benzoxadiazol-5-ylmethyl)pyrazol-4-yl]-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC3=CC4=NON=C4C=C3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 DFBVARVABSDNCV-UHFFFAOYSA-N 0.000 claims description 2
- XSAAHTFHNKFPNW-UHFFFAOYSA-N 7-[1-[(2,5-dichlorophenyl)methyl]pyrazol-4-yl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C(=CC=C(Cl)C=3)Cl)N=C2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 XSAAHTFHNKFPNW-UHFFFAOYSA-N 0.000 claims description 2
- MYHARYFKAQQZMM-UHFFFAOYSA-N 7-[1-[(3-aminophenyl)methyl]pyrazol-4-yl]-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=C(N)C=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 MYHARYFKAQQZMM-UHFFFAOYSA-N 0.000 claims description 2
- XBQSCCQLFHQSJD-UHFFFAOYSA-N 7-[3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(ON=C2C)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 XBQSCCQLFHQSJD-UHFFFAOYSA-N 0.000 claims description 2
- AHPLJNPKWIXLLC-UHFFFAOYSA-N 7-[3-(3,5-dimethyl-1h-pyrazol-4-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(NN=C2C)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 AHPLJNPKWIXLLC-UHFFFAOYSA-N 0.000 claims description 2
- QTAVJFWUXAOGCR-UHFFFAOYSA-N 7-[3-(3-aminopropylsulfonyl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)CCCN)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 QTAVJFWUXAOGCR-UHFFFAOYSA-N 0.000 claims description 2
- RYWMDXDWVSSEPC-UHFFFAOYSA-N 7-[3-(3-cyclopropyl-5-methyl-1h-pyrazol-4-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(NN=C2C)C2CC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 RYWMDXDWVSSEPC-UHFFFAOYSA-N 0.000 claims description 2
- OCLLIGFYGZHCQI-UHFFFAOYSA-N 7-[3-(4-methylpiperazin-1-yl)sulfonylphenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=CN=C3C=2)=C1 OCLLIGFYGZHCQI-UHFFFAOYSA-N 0.000 claims description 2
- ZOYITUNLCDHCJW-UHFFFAOYSA-N 7-[3-(5-amino-2-methylthiophen-3-yl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)C2=C(SC(N)=C2)C)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 ZOYITUNLCDHCJW-UHFFFAOYSA-N 0.000 claims description 2
- MDDJVEBBFLQMIG-UHFFFAOYSA-N 7-[3-(aminomethyl)phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CN)C=CC=2)=N1 MDDJVEBBFLQMIG-UHFFFAOYSA-N 0.000 claims description 2
- TXFDEBRJWSOAFQ-UHFFFAOYSA-N 7-[3-(diethylamino)pyrrolidin-1-yl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1C(N(CC)CC)CCN1C1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 TXFDEBRJWSOAFQ-UHFFFAOYSA-N 0.000 claims description 2
- QQDAPZQSEASFIW-UHFFFAOYSA-N 7-[3-(methylaminomethyl)phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CNCC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=CN=C3C=2)=C1 QQDAPZQSEASFIW-UHFFFAOYSA-N 0.000 claims description 2
- AATNTJQPQQQBGQ-UHFFFAOYSA-N 7-[3-[(cyclopropylmethylamino)methyl]phenyl]-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNCC3CC3)C=CC=2)=N1 AATNTJQPQQQBGQ-UHFFFAOYSA-N 0.000 claims description 2
- AETIMTKIXAUWJV-UHFFFAOYSA-N 7-[3-[(dimethylamino)methyl]-1-ethylsulfonylindol-6-yl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=C2N(S(=O)(=O)CC)C=C(CN(C)C)C2=CC=C1C(N=1)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 AETIMTKIXAUWJV-UHFFFAOYSA-N 0.000 claims description 2
- ZBAYWIKUKPUVIC-UHFFFAOYSA-N 7-[3-[2-(dimethylamino)ethoxy]phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CN(C)CCOC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 ZBAYWIKUKPUVIC-UHFFFAOYSA-N 0.000 claims description 2
- ZJBCLKIVGXYVOI-UHFFFAOYSA-N CC1=CC(C(N)(N(CC=N2)C2=C2)N=C2N)=NN1 Chemical class CC1=CC(C(N)(N(CC=N2)C2=C2)N=C2N)=NN1 ZJBCLKIVGXYVOI-UHFFFAOYSA-N 0.000 claims description 2
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims description 2
- GLGIYDRFAKEOES-UHFFFAOYSA-N [3-[(7-phenylimidazo[1,2-c]pyrimidin-5-yl)amino]-1h-pyrazol-5-yl]methanol Chemical compound N1C(CO)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=CC=CC=2)=N1 GLGIYDRFAKEOES-UHFFFAOYSA-N 0.000 claims description 2
- AHGWVMGORPUDIT-UHFFFAOYSA-N [5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-7-(3-ethylsulfonylphenyl)imidazo[1,2-c]pyrimidin-2-yl]methanol Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(CO)N=C3C=2)=C1 AHGWVMGORPUDIT-UHFFFAOYSA-N 0.000 claims description 2
- DURKWYKYYAVXDM-UHFFFAOYSA-N [7-(3-ethylsulfonylphenyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-2-yl]methanol Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(CO)N=C3C=2)=C1 DURKWYKYYAVXDM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000005336 allyloxy group Chemical group 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 2
- JXPIMUCXJYUKIK-UHFFFAOYSA-N but-2-ynyl n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]carbamate Chemical compound C1=CC(NC(=O)OCC#CC)=CC=C1SC1=CC2=NC=CN2C(NC2=NNC(=C2)C2CC2)=N1 JXPIMUCXJYUKIK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 229940047889 isobutyramide Drugs 0.000 claims description 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- YDOQGSFPEWLAKN-UHFFFAOYSA-N methyl 3-[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 YDOQGSFPEWLAKN-UHFFFAOYSA-N 0.000 claims description 2
- RVUXRYWMGJASCA-UHFFFAOYSA-N methyl 4-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1N=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 RVUXRYWMGJASCA-UHFFFAOYSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 2
- ONRNZCSJNWMBKI-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-(ethoxymethyl)-7-(3-ethylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C=2C=C(C=CC=2)S(=O)(=O)CC)=CC2=NC(COCC)=CN2C=1NC(=NN1)C=C1C1CC1 ONRNZCSJNWMBKI-UHFFFAOYSA-N 0.000 claims description 2
- WFYAEANAIZADDY-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CCN3CCOCC3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 WFYAEANAIZADDY-UHFFFAOYSA-N 0.000 claims description 2
- AZIJEPBVMATVKF-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(3-methylbutyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=NN(CCC(C)C)C=C1C1=CC2=NC(C)=CN2C(NC2=NNC(=C2)C2CC2)=N1 AZIJEPBVMATVKF-UHFFFAOYSA-N 0.000 claims description 2
- UYANHYRKBSXTHC-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(pyridin-2-ylmethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3N=CC=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 UYANHYRKBSXTHC-UHFFFAOYSA-N 0.000 claims description 2
- DLQXOLXQCSNNCE-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-(quinolin-8-ylmethyl)pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C4=NC=CC=C4C=CC=3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 DLQXOLXQCSNNCE-UHFFFAOYSA-N 0.000 claims description 2
- VTMWPYSEQYVEKS-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(3-nitrophenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)[N+]([O-])=O)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 VTMWPYSEQYVEKS-UHFFFAOYSA-N 0.000 claims description 2
- LKRDPFBOIUVFPF-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(3-pyrrol-1-ylphenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=C(C=CC=3)N3C=CC=C3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 LKRDPFBOIUVFPF-UHFFFAOYSA-N 0.000 claims description 2
- JTFDLBWMTYKDHH-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(4-pyrazol-1-ylphenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=CC(=CC=3)N3N=CC=C3)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 JTFDLBWMTYKDHH-UHFFFAOYSA-N 0.000 claims description 2
- MELKKSOYORGVIB-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(2,3-dihydro-1-benzofuran-5-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CC1C1=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C3CCOC3=CC=2)=NN1 MELKKSOYORGVIB-UHFFFAOYSA-N 0.000 claims description 2
- QCLFRXLRKRKCCI-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(2,3-dihydroindol-1-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CC1C1=CC(NC=2N3C=CN=C3C=C(N=2)N2C3=CC=CC=C3CC2)=NN1 QCLFRXLRKRKCCI-UHFFFAOYSA-N 0.000 claims description 2
- NGMPKDXNIYGWOQ-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(3,4-dihydro-1h-isoquinolin-2-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound C1CC1C1=CC(NC=2N3C=CN=C3C=C(N=2)N2CC3=CC=CC=C3CC2)=NN1 NGMPKDXNIYGWOQ-UHFFFAOYSA-N 0.000 claims description 2
- BOGQGBDABAFWMP-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(3-ethylsulfonylphenyl)-2-[(4-methylpiperazin-1-yl)methyl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(CN4CCN(C)CC4)N=C3C=2)=C1 BOGQGBDABAFWMP-UHFFFAOYSA-N 0.000 claims description 2
- OHAIZFBNNWKUIM-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-(3-ethylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound CCS(=O)(=O)C1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=CN=C3C=2)=C1 OHAIZFBNNWKUIM-UHFFFAOYSA-N 0.000 claims description 2
- YZWBADIZXZDZPW-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(2,3-dimethoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1OC YZWBADIZXZDZPW-UHFFFAOYSA-N 0.000 claims description 2
- RLFRRBJZIHHNGJ-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(3,5-dimethoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC(OC)=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 RLFRRBJZIHHNGJ-UHFFFAOYSA-N 0.000 claims description 2
- DWFQRZNROTUJJE-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(3-methoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 DWFQRZNROTUJJE-UHFFFAOYSA-N 0.000 claims description 2
- LGERUKVWJHEAEY-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-7-[1-[(4-methoxyphenyl)methyl]pyrazol-4-yl]-2-methylimidazo[1,2-c]pyrimidin-5-amine Chemical compound C1=CC(OC)=CC=C1CN1N=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 LGERUKVWJHEAEY-UHFFFAOYSA-N 0.000 claims description 2
- HLOFFXFIJVZECX-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2,7-diphenylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=C(N=C3C=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 HLOFFXFIJVZECX-UHFFFAOYSA-N 0.000 claims description 2
- VPQBXMMVYAODPG-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-phenylimidazo[1,2-a]pyrazin-8-amine Chemical compound N1C(C)=CC(NC=2C3=NC=CN3C=C(N=2)C=2C=CC=CC=2)=N1 VPQBXMMVYAODPG-UHFFFAOYSA-N 0.000 claims description 2
- ZKAAGHMZAJSBGN-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-piperidin-1-ylimidazo[1,2-a]pyrazin-8-amine Chemical compound N1C(C)=CC(NC=2C3=NC=CN3C=C(N=2)N2CCCCC2)=N1 ZKAAGHMZAJSBGN-UHFFFAOYSA-N 0.000 claims description 2
- WFWLQEJPFGTKQP-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-(1,2,3,4-tetrahydroisoquinolin-7-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical class N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C3CNCCC3=CC=2)=N1 WFWLQEJPFGTKQP-UHFFFAOYSA-N 0.000 claims description 2
- LTVLIBKBGHODBB-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-(2-methylsulfonyl-3,4-dihydro-1h-isoquinolin-7-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C3CN(CCC3=CC=2)S(C)(=O)=O)=N1 LTVLIBKBGHODBB-UHFFFAOYSA-N 0.000 claims description 2
- GXIPJBWNVDKOMB-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-(3-methylsulfonylphenyl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(C=CC=2)S(C)(=O)=O)=N1 GXIPJBWNVDKOMB-UHFFFAOYSA-N 0.000 claims description 2
- GZYUZBROUKLZAA-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-7-piperidin-1-ylimidazo[1,2-c]pyrimidin-5-amine Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)N2CCCCC2)=N1 GZYUZBROUKLZAA-UHFFFAOYSA-N 0.000 claims description 2
- JNLYNHDNQCEBGQ-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethoxy]-5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]cyclopropanesulfonamide Chemical compound CN(C)CCOC1=CC=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=C1NS(=O)(=O)C1CC1 JNLYNHDNQCEBGQ-UHFFFAOYSA-N 0.000 claims description 2
- WKVNWHBJXLKDMT-UHFFFAOYSA-N n-[2-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 WKVNWHBJXLKDMT-UHFFFAOYSA-N 0.000 claims description 2
- NMEKGDXDEWKVJY-UHFFFAOYSA-N n-[2-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N=1C(C=2C(=CC=CC=2)NS(C)(=O)=O)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 NMEKGDXDEWKVJY-UHFFFAOYSA-N 0.000 claims description 2
- RHBIBVBVJHEJEW-UHFFFAOYSA-N n-[3-[2-(hydroxymethyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N1C(C)=CC(NC=2N3C=C(CO)N=C3C=C(N=2)C=2C=C(NS(C)(=O)=O)C=CC=2)=N1 RHBIBVBVJHEJEW-UHFFFAOYSA-N 0.000 claims description 2
- PPLSEHYNYVUXJH-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-(hydroxymethyl)imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=C(CO)N=C3C=2)=C1 PPLSEHYNYVUXJH-UHFFFAOYSA-N 0.000 claims description 2
- BTCWEXSFTBTCHL-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[(4-methylpiperazin-1-yl)methyl]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C1CN(C)CCN1CC1=CN(C(NC2=NNC(=C2)C2CC2)=NC(=C2)C=3C=C(NS(C)(=O)=O)C=CC=3)C2=N1 BTCWEXSFTBTCHL-UHFFFAOYSA-N 0.000 claims description 2
- YQTJPLAZZVSTFZ-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(SC=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 YQTJPLAZZVSTFZ-UHFFFAOYSA-N 0.000 claims description 2
- MILFCSCDTPTHNF-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=CN=C3C=2)=C1 MILFCSCDTPTHNF-UHFFFAOYSA-N 0.000 claims description 2
- CNNMOOWTPIVKQN-UHFFFAOYSA-N n-[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N=C(NC=3NN=C(C=3)C3CC3)N3C=CN=C3C=2)=C1 CNNMOOWTPIVKQN-UHFFFAOYSA-N 0.000 claims description 2
- MKUDBHGZQHOIKV-UHFFFAOYSA-N n-[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N1N=C(C)C=C1NC1=NC(C=2C=C(NS(C)(=O)=O)C=CC=2)=CC2=NC=CN12 MKUDBHGZQHOIKV-UHFFFAOYSA-N 0.000 claims description 2
- JTZJXBCFJBHHAX-UHFFFAOYSA-N n-[3-[[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]phenyl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC=CC(CN2N=CC(=C2)C=2N=C(NC3=NNC(=C3)C3CC3)N3C=C(C)N=C3C=2)=C1 JTZJXBCFJBHHAX-UHFFFAOYSA-N 0.000 claims description 2
- QVSDSLSMBVIGBP-UHFFFAOYSA-N n-[4-[2-(hydroxymethyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=C(CO)N=C3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 QVSDSLSMBVIGBP-UHFFFAOYSA-N 0.000 claims description 2
- MQLLYGMTCOEXND-UHFFFAOYSA-N n-[4-[2-(methylaminomethyl)-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3CC3)=CC=2)=CC2=NC(CNC)=CN2C=1NC=1C=C(C)NN=1 MQLLYGMTCOEXND-UHFFFAOYSA-N 0.000 claims description 2
- POGGWKADGDCMQM-UHFFFAOYSA-N n-[4-[2-[(2-hydroxyethylamino)methyl]-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=C(CNCCO)N=C3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 POGGWKADGDCMQM-UHFFFAOYSA-N 0.000 claims description 2
- OKGVUECBUKZCEW-UHFFFAOYSA-N n-[4-[2-[(dimethylamino)methyl]-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3CC3)=CC=2)=CC2=NC(CN(C)C)=CN2C=1NC=1C=C(C)NN=1 OKGVUECBUKZCEW-UHFFFAOYSA-N 0.000 claims description 2
- PINFCAYNXOYQLC-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-1,2-oxazole-5-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C=3ON=CC=3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 PINFCAYNXOYQLC-UHFFFAOYSA-N 0.000 claims description 2
- KNXCBOOEGDKLLA-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=CC2=NC(C)=CN2C(NC2=NNC(C)=C2)=N1 KNXCBOOEGDKLLA-UHFFFAOYSA-N 0.000 claims description 2
- BULOJFGDSWJZLE-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3CC3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 BULOJFGDSWJZLE-UHFFFAOYSA-N 0.000 claims description 2
- RDGCAFVJLOGBOC-UHFFFAOYSA-N n-[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]furan-2-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C=3OC=CC=3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 RDGCAFVJLOGBOC-UHFFFAOYSA-N 0.000 claims description 2
- BGNGXBCGISADRM-UHFFFAOYSA-N n-[4-[2-methyl-8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1=C(NC2=NNC(C)=C2)C2=NC(C)=CN2C=C1SC(C=C1)=CC=C1NC(=O)C1CC1 BGNGXBCGISADRM-UHFFFAOYSA-N 0.000 claims description 2
- NNAKLZSAAGXJII-UHFFFAOYSA-N n-[4-[3-methyl-8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2C3=NC=C(C)N3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 NNAKLZSAAGXJII-UHFFFAOYSA-N 0.000 claims description 2
- YVKFZSRJUICEEK-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-(methoxymethyl)imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-2-methoxyacetamide Chemical compound C1=CC(NC(=O)COC)=CC=C1SC1=CC2=NC(COC)=CN2C(NC2=NNC(=C2)C2CC2)=N1 YVKFZSRJUICEEK-UHFFFAOYSA-N 0.000 claims description 2
- NMGQHZSDJYLJRB-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[(dimethylamino)methyl]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound N=1C(SC=2C=CC(NC(C)=O)=CC=2)=CC2=NC(CN(C)C)=CN2C=1NC(=NN1)C=C1C1CC1 NMGQHZSDJYLJRB-UHFFFAOYSA-N 0.000 claims description 2
- XNZQABBSBCFIOW-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-1,5-dimethylpyrazole-3-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C3=NN(C)C(C)=C3)=CC=2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 XNZQABBSBCFIOW-UHFFFAOYSA-N 0.000 claims description 2
- XWFCAOGLMUJWRL-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-2,5-dimethylpyrazole-3-carboxamide Chemical compound CN1N=C(C)C=C1C(=O)NC(C=C1)=CC=C1SC1=CC2=NC(C)=CN2C(NC2=NNC(=C2)C2CC2)=N1 XWFCAOGLMUJWRL-UHFFFAOYSA-N 0.000 claims description 2
- WDEFALGXDKDULP-UHFFFAOYSA-N n-[4-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-methylimidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]-5-methylfuran-2-carboxamide Chemical compound N=1C(SC=2C=CC(NC(=O)C=3OC(C)=CC=3)=CC=2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 WDEFALGXDKDULP-UHFFFAOYSA-N 0.000 claims description 2
- CYIOGEPASGEMLP-UHFFFAOYSA-N n-[4-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrimidin-7-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC2=NC=CN2C(NC2=NNC(C)=C2)=C1 CYIOGEPASGEMLP-UHFFFAOYSA-N 0.000 claims description 2
- RMVNHLFCNRUPDK-UHFFFAOYSA-N n-[4-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrimidin-7-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3N=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)C=2)=N1 RMVNHLFCNRUPDK-UHFFFAOYSA-N 0.000 claims description 2
- ZIDATLVNPVBACP-UHFFFAOYSA-N n-[4-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]sulfanylphenyl]oxolane-2-carboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(SC=3C=CC(NC(=O)C4OCCC4)=CC=3)N=2)=N1 ZIDATLVNPVBACP-UHFFFAOYSA-N 0.000 claims description 2
- QZXDISDNIDKGEH-UHFFFAOYSA-N n-[4-[6-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-8-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC2=NNC(C)=C2)=CN2C1=NC=C2 QZXDISDNIDKGEH-UHFFFAOYSA-N 0.000 claims description 2
- OBIROORVJGREFD-UHFFFAOYSA-N n-[4-[6-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-8-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)C3=NC=CN3C=2)=N1 OBIROORVJGREFD-UHFFFAOYSA-N 0.000 claims description 2
- JCNSRZSTPRJMFY-UHFFFAOYSA-N n-[4-[8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC(N=C1NC2=NNC(C)=C2)=CN2C1=NC=C2 JCNSRZSTPRJMFY-UHFFFAOYSA-N 0.000 claims description 2
- MAPCSAGZTZJTIK-UHFFFAOYSA-N n-[4-[8-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-a]pyrazin-6-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2C3=NC=CN3C=C(SC=3C=CC(NC(=O)C4CC4)=CC=3)N=2)=N1 MAPCSAGZTZJTIK-UHFFFAOYSA-N 0.000 claims description 2
- BXYGAGCLZPUAIB-UHFFFAOYSA-N n-[5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]-2-(2-morpholin-4-ylethoxy)phenyl]cyclopropanesulfonamide Chemical compound N=1C(C=2C=C(NS(=O)(=O)C3CC3)C(OCCN3CCOCC3)=CC=2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 BXYGAGCLZPUAIB-UHFFFAOYSA-N 0.000 claims description 2
- FKZDBAMCOCDDGR-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 FKZDBAMCOCDDGR-UHFFFAOYSA-N 0.000 claims description 2
- WUVZWWRIURNSOM-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopentanecarboxamide Chemical compound C1CCCC1C(=O)NCC(C=1)=CC=CC=1C(N=1)=CC2=NC=CN2C=1NC(=NN1)C=C1C1CC1 WUVZWWRIURNSOM-UHFFFAOYSA-N 0.000 claims description 2
- OXFVZRQAFFEJGX-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCC(C=1)=CC=CC=1C(N=1)=CC2=NC=CN2C=1NC(=NN1)C=C1C1CC1 OXFVZRQAFFEJGX-UHFFFAOYSA-N 0.000 claims description 2
- STGDPPYTPHYUKB-UHFFFAOYSA-N n-[[3-[5-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CC=CC(C=2N=C(NC3=NNC(=C3)C3CC3)N3C=CN=C3C=2)=C1 STGDPPYTPHYUKB-UHFFFAOYSA-N 0.000 claims description 2
- SAMFUIMKMTZLDQ-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]azetidine-3-carboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)C3CNC3)C=CC=2)=N1 SAMFUIMKMTZLDQ-UHFFFAOYSA-N 0.000 claims description 2
- MNGHTLDQGOLCSD-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)C3CC3)C=CC=2)=N1 MNGHTLDQGOLCSD-UHFFFAOYSA-N 0.000 claims description 2
- JZCYCFNAOXZGOS-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanesulfonamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNS(=O)(=O)C3CC3)C=CC=2)=N1 JZCYCFNAOXZGOS-UHFFFAOYSA-N 0.000 claims description 2
- NMZCCRDYLSGLFD-UHFFFAOYSA-N n-[[4-fluoro-3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound N=1C(C=2C(=CC=C(CNC(=O)C3CC3)C=2)F)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 NMZCCRDYLSGLFD-UHFFFAOYSA-N 0.000 claims description 2
- DMVQCFZDIMWKOW-UHFFFAOYSA-N n-[[4-fluoro-3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclopropanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C(=CC=C(CNC(=O)C3CC3)C=2)F)=N1 DMVQCFZDIMWKOW-UHFFFAOYSA-N 0.000 claims description 2
- FVBNFGJCTMZTJD-UHFFFAOYSA-N n-cyclopropyl-5-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]thiophene-2-carboxamide Chemical compound N=1C(C=2SC(=CC=2)C(=O)NC2CC2)=CC2=NC(C)=CN2C=1NC=1C=C(C)NN=1 FVBNFGJCTMZTJD-UHFFFAOYSA-N 0.000 claims description 2
- SZRPNHVPLCLXOD-UHFFFAOYSA-N n-ethyl-4-[[4-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]pyrazol-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CN1N=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 SZRPNHVPLCLXOD-UHFFFAOYSA-N 0.000 claims description 2
- BQSMTUBJVMUNBP-UHFFFAOYSA-N n-ethyl-n-[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]-2-propan-2-ylimidazo[1,2-c]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CCN(S(C)(=O)=O)C1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(N=C3C=2)C(C)C)=C1 BQSMTUBJVMUNBP-UHFFFAOYSA-N 0.000 claims description 2
- YVXCZYSZTJVOHE-UHFFFAOYSA-N n-methyl-n-[[3-[2-methyl-5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]ethanesulfonamide Chemical compound CCS(=O)(=O)N(C)CC1=CC=CC(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)=C1 YVXCZYSZTJVOHE-UHFFFAOYSA-N 0.000 claims description 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 2
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 2
- XIMBESZRBTVIOD-UHFFFAOYSA-N piperidine-2-carboxamide Chemical compound NC(=O)C1CCCCN1 XIMBESZRBTVIOD-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 claims description 2
- SJMCLWCCNYAWRQ-UHFFFAOYSA-N propane-2-sulfonamide Chemical compound CC(C)S(N)(=O)=O SJMCLWCCNYAWRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940080818 propionamide Drugs 0.000 claims description 2
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims description 2
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims description 2
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims description 2
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- IHVBPMAJQOWPBQ-UHFFFAOYSA-N 7-[4-methoxy-3-(oxan-4-ylsulfonyl)phenyl]-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine Chemical compound COC1=CC=C(C=2N=C(NC3=NNC(C)=C3)N3C=C(C)N=C3C=2)C=C1S(=O)(=O)C1CCOCC1 IHVBPMAJQOWPBQ-UHFFFAOYSA-N 0.000 claims 1
- GHMWFUVGWJRZAJ-UHFFFAOYSA-N CC1=CN2C(=N1)C=C(N=C2NC3=NNC(=C3)C4CC4)C5=CN(N=C5)CC6=CC(=CC=C6)C(=O)O Chemical compound CC1=CN2C(=N1)C=C(N=C2NC3=NNC(=C3)C4CC4)C5=CN(N=C5)CC6=CC(=CC=C6)C(=O)O GHMWFUVGWJRZAJ-UHFFFAOYSA-N 0.000 claims 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 229940043355 kinase inhibitor Drugs 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- QSLLFYVBWXWUQT-UHFFFAOYSA-N 7-Azaindolizine Chemical compound C1=NC=CN2C=CC=C21 QSLLFYVBWXWUQT-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LNMNAZRUZGGUMY-UHFFFAOYSA-N 1,2-dihydro-pyrrolo[3,2,1-hi]indole Chemical compound C1=CC2=CC=CC3=C2N1CC3 LNMNAZRUZGGUMY-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- INSWZAQOISIYDT-UHFFFAOYSA-N imidazo[1,2-a]pyrimidine Chemical compound C1=CC=NC2=NC=CN21 INSWZAQOISIYDT-UHFFFAOYSA-N 0.000 description 1
- PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical compound C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 description 1
- JMANUKZDKDKBJP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical compound C1=CC=CC2=CN=CN21 JMANUKZDKDKBJP-UHFFFAOYSA-N 0.000 description 1
- LXYHLTOJFGNEKG-UHFFFAOYSA-N imidazo[1,5-a]pyrimidine Chemical compound C1=CC=NC2=CN=CN21 LXYHLTOJFGNEKG-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- JARBKLORKARLFJ-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methyl-7-[1-[(4-methylsulfonylphenyl)methyl]pyrazol-4-yl]imidazo[1,2-c]pyrimidin-5-amine Chemical compound N=1C(C2=CN(CC=3C=CC(=CC=3)S(C)(=O)=O)N=C2)=CC2=NC(C)=CN2C=1NC(=NN1)C=C1C1CC1 JARBKLORKARLFJ-UHFFFAOYSA-N 0.000 description 1
- WYUZPNKVHCZFED-UHFFFAOYSA-N n-[[3-[5-[(5-methyl-1h-pyrazol-3-yl)amino]imidazo[1,2-c]pyrimidin-7-yl]phenyl]methyl]cyclobutanecarboxamide Chemical compound N1C(C)=CC(NC=2N3C=CN=C3C=C(N=2)C=2C=C(CNC(=O)C3CCC3)C=CC=2)=N1 WYUZPNKVHCZFED-UHFFFAOYSA-N 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VUVGMQNYJPPCCC-UHFFFAOYSA-N pyrido[1,2-a]indole Chemical compound C1=CC=CC2=CC3=CC=CC=C3N21 VUVGMQNYJPPCCC-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JBDKAABFESSFMV-UHFFFAOYSA-N pyrrolo[1,2-a]pyrimidine Chemical compound N1=CC=CN2C=CC=C21 JBDKAABFESSFMV-UHFFFAOYSA-N 0.000 description 1
- NISJKLIMPQPAQS-UHFFFAOYSA-N pyrrolo[1,2-b]pyridazine Chemical compound C1=CC=NN2C=CC=C21 NISJKLIMPQPAQS-UHFFFAOYSA-N 0.000 description 1
- RIEKLTCRUGDAPM-UHFFFAOYSA-N pyrrolo[1,2-c]pyrimidine Chemical compound C1=CN=CN2C=CC=C21 RIEKLTCRUGDAPM-UHFFFAOYSA-N 0.000 description 1
- WMHRXFNTQPIYDT-UHFFFAOYSA-N pyrrolo[2,3-b]pyrazine Chemical compound C1=C[N]C2=NC=CC2=N1 WMHRXFNTQPIYDT-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- GDQBPBMIAFIRIU-UHFFFAOYSA-N thieno[2,3-c]pyridine Chemical compound C1=NC=C2SC=CC2=C1 GDQBPBMIAFIRIU-UHFFFAOYSA-N 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QQOWHRYOXYEMTL-UHFFFAOYSA-N triazin-4-amine Chemical compound N=C1C=CN=NN1 QQOWHRYOXYEMTL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61930204P | 2004-10-15 | 2004-10-15 | |
| US67969005P | 2005-05-11 | 2005-05-11 | |
| PCT/US2005/037059 WO2006044687A2 (en) | 2004-10-15 | 2005-10-14 | Kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011284364A Division JP5524171B2 (ja) | 2004-10-15 | 2011-12-26 | キナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516973A JP2008516973A (ja) | 2008-05-22 |
| JP2008516973A5 true JP2008516973A5 (https=) | 2008-12-04 |
Family
ID=35677430
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536949A Withdrawn JP2008516973A (ja) | 2004-10-15 | 2005-10-14 | キナーゼ阻害剤 |
| JP2011284364A Expired - Fee Related JP5524171B2 (ja) | 2004-10-15 | 2011-12-26 | キナーゼ阻害剤 |
| JP2013006060A Ceased JP2013121966A (ja) | 2004-10-15 | 2013-01-17 | キナーゼ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011284364A Expired - Fee Related JP5524171B2 (ja) | 2004-10-15 | 2011-12-26 | キナーゼ阻害剤 |
| JP2013006060A Ceased JP2013121966A (ja) | 2004-10-15 | 2013-01-17 | キナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7713973B2 (https=) |
| EP (1) | EP1812439B2 (https=) |
| JP (3) | JP2008516973A (https=) |
| AT (1) | ATE479687T1 (https=) |
| DE (1) | DE602005023333D1 (https=) |
| WO (1) | WO2006044687A2 (https=) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003284237A1 (en) * | 2002-10-16 | 2004-05-04 | Transport Systems, Inc. | Monorail sortation system |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
| WO2006127587A1 (en) * | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US7232901B2 (en) * | 2005-07-01 | 2007-06-19 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| CA2615374A1 (en) * | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
| CA2622352C (en) * | 2005-09-30 | 2014-05-27 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| HRP20140688T1 (hr) * | 2006-07-07 | 2014-10-24 | Bristol-Myers Squibb Company | Inhibitori piroltriazin kinaze |
| US7605160B2 (en) * | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2662337A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | 癌の治療法 |
| PE20080931A1 (es) * | 2006-11-08 | 2008-07-19 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| US8148522B2 (en) * | 2007-01-02 | 2012-04-03 | Bristol-Myers Squibb Company | Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate |
| EP2111405B1 (en) * | 2007-01-08 | 2010-10-27 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates |
| DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| EP2125819B1 (en) * | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| CN101687874B (zh) | 2007-04-18 | 2013-01-30 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| AU2008262291A1 (en) * | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| RU2461551C2 (ru) * | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| DE102007060172A1 (de) | 2007-12-13 | 2009-06-25 | Bayer Healthcare Ag | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| DE102008035209A1 (de) | 2008-07-29 | 2010-02-04 | Bayer Schering Pharma Aktiengesellschaft | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| PE20091074A1 (es) * | 2007-12-13 | 2009-07-26 | Bayer Healthcare Ag | Triazolotriazinas y triazolopirazinas y su uso |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| CA2710929A1 (en) * | 2008-01-28 | 2009-08-06 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| US8476430B2 (en) | 2008-07-24 | 2013-07-02 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8445676B2 (en) * | 2008-10-08 | 2013-05-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EA021293B1 (ru) * | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN102307474B (zh) | 2008-12-08 | 2015-04-01 | 吉利德康涅狄格股份有限公司 | 咪唑并吡嗪syk抑制剂 |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| JP5487214B2 (ja) | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| US20130310362A1 (en) * | 2009-02-13 | 2013-11-21 | Bayer Pharma Aktiegesellschaft | Fused pyrimidines |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| WO2011088045A1 (en) | 2010-01-12 | 2011-07-21 | Ambit Biosciences Corporation | Aurora kinase compounds and methods of their use |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| JP5093527B2 (ja) * | 2010-02-10 | 2012-12-12 | 日本電気株式会社 | 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路 |
| CN103168039B (zh) | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
| KR20130094710A (ko) * | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
| US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014210087A1 (en) | 2013-06-25 | 2014-12-31 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| TWI648272B (zh) | 2013-06-25 | 2019-01-21 | 美商必治妥美雅史谷比公司 | 經取代之四氫咔唑及咔唑甲醯胺化合物 |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| CN105764516A (zh) | 2013-12-04 | 2016-07-13 | 吉利德科学公司 | 治疗癌症的方法 |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| EA034931B1 (ru) | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
| JP6592512B2 (ja) | 2014-10-24 | 2019-10-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 三環式アトロプ異性体の化合物 |
| SI3209651T1 (sl) | 2014-10-24 | 2019-12-31 | Bristol-Myers Squibb Company | Derivati karbazola |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JP6791979B2 (ja) * | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN109890824B (zh) | 2016-11-02 | 2022-05-24 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| MY193511A (en) | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| CN111018860B (zh) * | 2018-10-10 | 2022-06-10 | 中国药科大学 | 吡咯并三嗪类化合物及其应用 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| JP7535600B2 (ja) | 2020-06-01 | 2024-08-16 | ナンジン ルイジエ ファーマ シーオー．，エルティーディー． | 化合物および脾臓チロシンキナーゼ阻害剤としてのその使用 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2026064361A1 (en) * | 2024-09-20 | 2026-03-26 | Fmc Corporation | Linked bicyclic compounds as pesticides |
Family Cites Families (193)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB828847A (en) | 1956-12-14 | 1960-02-24 | Ilford Ltd | Improvements in or relating to cyanine dyes |
| FR1242962A (fr) | 1959-08-25 | 1960-10-07 | Kodak Pathe | Nouveau procédé pour la préparation de colorants sensibilisateurs de la série des cyanines et des mérocyanines et produits obtenus |
| DE2844606A1 (de) | 1978-10-13 | 1980-04-24 | Bayer Ag | Heterocyclische farbstoffe |
| US4260776A (en) | 1978-01-25 | 1981-04-07 | Bayer Aktiengesellschaft | Heterocyclic dyestuffs |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| EP1655369A1 (en) | 1995-12-18 | 2006-05-10 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| US7119174B2 (en) | 1995-12-18 | 2006-10-10 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
| US6057329A (en) | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE342971T1 (de) | 1997-08-15 | 2006-11-15 | Univ Hiroshima | Den zellzyklus regulierende proteine |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US6143480A (en) | 1998-09-03 | 2000-11-07 | Fuji Photo Film Co., Ltd. | Leuco dye and image recording medium containing the same |
| US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US20050113460A1 (en) | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DE60026297T2 (de) * | 1999-05-21 | 2006-11-02 | Bristol-Myers Squibb Co. | Pyrrolotriazin kinasehemmer |
| JP2003505064A (ja) | 1999-07-21 | 2003-02-12 | ユニバーシティー オブ マサチューセッツ | キナーゼ遮断ポリペプチド及びその使用 |
| WO2001014378A1 (en) * | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES |
| KR20020032608A (ko) | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 화합물 및 이를 함유하는 제약 조성물 |
| GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US7709479B1 (en) | 1999-09-21 | 2010-05-04 | Astrazeneca | Quinazoline derivatives and their use as pharmaceuticals |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| OA12514A (en) | 1999-12-24 | 2006-05-29 | Aventis Pharma Ltd | Azaindoles. |
| US6977259B2 (en) | 2000-01-28 | 2005-12-20 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| HUP0202332A2 (en) | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
| CA2369076A1 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| EP1134221A1 (en) | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| EP1209158A1 (en) | 2000-11-18 | 2002-05-29 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines |
| JP2001294772A (ja) | 2000-04-10 | 2001-10-23 | Fuji Photo Film Co Ltd | 着色組成物、インクジェット用インク及びインクジェット記録方法 |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| ATE394102T1 (de) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| ES2349762T3 (es) | 2000-08-10 | 2011-01-11 | Pfizer Italia S.R.L. | Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. |
| US6352858B1 (en) | 2000-09-11 | 2002-03-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of BTAK expression |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6867300B2 (en) † | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| AU2002215053A1 (en) | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| CZ20031315A3 (cs) | 2000-11-28 | 2004-04-14 | Pfizer Products Inc. | Soli isothiazolkarboxamidu a jejich použití jako prostředků proti hyperproliferaci |
| FR2818278B1 (fr) * | 2000-12-20 | 2003-02-28 | Sod Conseils Rech Applic | Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| EP1345941A1 (fr) * | 2000-12-20 | 2003-09-24 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| CA2447405C (en) | 2001-05-14 | 2006-10-17 | Pfizer Products Inc. | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| CA2448076A1 (en) | 2001-05-24 | 2002-11-28 | Masahiko Hayakawa | 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives |
| WO2002096867A2 (en) | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| US6762179B2 (en) | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| CA2446756C (en) | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| DE10130167A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| JP2004535493A (ja) | 2001-06-22 | 2004-11-25 | ザ プロクター アンド ギャンブル カンパニー | 親油性流体系用の布地ケア組成物 |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| ATE345341T1 (de) | 2001-07-19 | 2006-12-15 | Pfizer Italia Srl | Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel |
| US20040235867A1 (en) | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| AU2002322775A1 (en) | 2001-07-27 | 2003-02-17 | The Regents Of The University Of California | Stk15 (stk6) gene polymorphism and methods of determining cancer risk |
| WO2003011287A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
| EP1435948A1 (en) | 2001-08-06 | 2004-07-14 | Pharmacia Italia S.p.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| JP2005507892A (ja) | 2001-09-19 | 2005-03-24 | ファルマシア・コーポレーション | 炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物 |
| ATE363473T1 (de) | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| MXPA04002667A (es) | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos de pirazolilo sustituido para el tratamiento de la inflacion. |
| BR0212613A (pt) | 2001-09-19 | 2004-08-31 | Pharmacia Corp | Compostos de indazol substituìdos para o tratamento de inflamação |
| WO2003028720A1 (en) | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| ATE407678T1 (de) | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| US20040010027A1 (en) | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| DE60234125D1 (de) | 2001-12-24 | 2009-12-03 | Astrazeneca Ab | E inhibitoren |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| WO2003078423A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
| EP1485100B1 (en) | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| DE60327999D1 (de) | 2002-03-15 | 2009-07-30 | Vertex Pharma | Azolylaminoazine als inhibitoren von proteinkinasen |
| SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| AU2003244978A1 (en) | 2002-04-15 | 2003-10-27 | Inserm | Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions |
| AU2003237121A1 (en) | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| EP1549318B1 (en) | 2002-05-01 | 2010-02-17 | Vertex Pharmaceuticals Incorporated | Crystal structure of aurora-2 protein and binding pockets thereof |
| JP4751063B2 (ja) | 2002-05-17 | 2011-08-17 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物 |
| WO2003101983A1 (en) | 2002-05-31 | 2003-12-11 | Yamanouchi Pharmaceutical Co., Ltd. | Tetrahydropyran derivative |
| FR2840905B1 (fr) | 2002-06-12 | 2006-07-07 | Centre Nat Rech Scient | Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers |
| AU2002311176A1 (en) | 2002-06-12 | 2003-12-31 | Axia Biosciences, Inc. | Chfr protein-catalyzed polyubiquitination of aurora kinase a and aurora kinase b |
| ES2282647T3 (es) | 2002-06-14 | 2007-10-16 | MERCK & CO., INC. | Inhibidores de cinesina mitotica. |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| DE10230605A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| DE10230604A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2004006838A2 (en) | 2002-07-15 | 2004-01-22 | Sugen, Inc. | Novel kinases |
| ES2304531T3 (es) | 2002-07-17 | 2008-10-16 | Pfizer Italia S.R.L. | Derivados heterobiciclicos de pirazol como inhibidores de quinasa. |
| CA2493680C (en) | 2002-07-25 | 2010-09-07 | Pharmacia Italia S.P.A. | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| TW200413378A (en) * | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| US20040157804A1 (en) | 2002-10-16 | 2004-08-12 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| US6909001B2 (en) | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| AU2003292435A1 (en) | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
| JP2006512387A (ja) | 2002-12-24 | 2006-04-13 | アストラゼネカ アクチボラグ | 化合物 |
| ES2290529T3 (es) | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
| MXPA05006920A (es) | 2002-12-24 | 2006-02-10 | Astrazeneca Ab | Compuestos de quinazolina. |
| CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
| ATE440087T1 (de) | 2003-01-30 | 2009-09-15 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| WO2004070062A2 (en) | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| CA2513716A1 (en) | 2003-02-14 | 2004-08-26 | Applied Research Systems Ars Holding N.V. | Piperazine-2-carboxamide derivatives |
| BRPI0407544A (pt) | 2003-02-17 | 2006-02-14 | Pharmacia Italia Spa | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| BR0318145A (pt) | 2003-02-26 | 2006-02-21 | Boehringer Ingelheim Pharma | dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento |
| MXPA05009719A (es) | 2003-03-11 | 2005-10-18 | Pharmacia Italia Spa | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. |
| WO2004083203A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| JP2006521398A (ja) * | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | ＴＧＦβの二−環式ピリミジン阻害剤 |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| WO2004090106A2 (en) | 2003-04-04 | 2004-10-21 | Vertex Pharmaceuticals Incorporated | Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design |
| CN1809557B (zh) | 2003-04-16 | 2012-07-04 | 阿斯利康(瑞典)有限公司 | 化合物 |
| CN1809536A (zh) | 2003-04-24 | 2006-07-26 | 麦克公司 | Akt活性抑制剂 |
| AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| ATE461179T1 (de) | 2003-04-24 | 2010-04-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
| EP1620095A4 (en) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| US20040242559A1 (en) | 2003-04-25 | 2004-12-02 | Aventis Pharma S.A. | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors |
| AU2004255153B2 (en) | 2003-05-01 | 2007-11-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| DK1618092T3 (da) | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
| WO2005000200A2 (en) | 2003-05-09 | 2005-01-06 | Sugen, Inc. | Novel kinases |
| PT1636236E (pt) | 2003-05-22 | 2013-12-16 | Nerviano Medical Sciences Srl | Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase |
| US7345046B2 (en) | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| ATE401080T1 (de) | 2003-06-02 | 2008-08-15 | Astrazeneca Ab | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs |
| TW200505452A (en) | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| WO2004113335A2 (en) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| WO2005009348A2 (en) | 2003-06-25 | 2005-02-03 | Ariad Pharmaceuticals, Inc. | Substituted purine derivatives |
| US20060178318A1 (en) | 2003-07-03 | 2006-08-10 | Shubha Anand | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| SI1641775T1 (sl) | 2003-07-03 | 2009-08-31 | Euro Celtique Sa | 2-piridin alkinski derivati, uporabni za zdravljenje bolečine |
| GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1648900A4 (en) | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | PHOSPHORUS MACROCYCLES |
| EP1781659B1 (en) | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| MXPA06000540A (es) | 2003-07-16 | 2006-03-30 | Janssen Pharmaceutica Nv | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa cinasa 3. |
| EP1654247B1 (en) | 2003-07-21 | 2010-01-20 | Merck Serono SA | Alkynyl aryl carboxamides |
| AU2004259357B2 (en) | 2003-07-24 | 2010-02-18 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
| US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
| US20050026984A1 (en) | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
| JP2007500178A (ja) | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| EP1648875A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| US7094791B2 (en) | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
| US7279575B2 (en) | 2003-08-08 | 2007-10-09 | Pfizer Italia S.R.L. | Pyrimidylpyrrole derivatives active as kinase inhibitors |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| AU2004267094A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| AU2004272306A1 (en) | 2003-09-12 | 2005-03-24 | Merck Serono Sa | Benzimidazole acetonitriles |
| AU2004272345A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| AU2004272346A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| ES2305844T3 (es) | 2003-09-16 | 2008-11-01 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de tirosina cinasa. |
| AU2003270848A1 (en) | 2003-09-17 | 2005-04-27 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
| EP1667684A1 (en) | 2003-09-17 | 2006-06-14 | ICOS Corporation | Use of chk1 inhibitors to control cell proliferation |
| US20070185007A1 (en) | 2003-09-19 | 2007-08-09 | Haolun Jin | Aza-quinolinol phosphonate integrase inhibitor compounds |
| US20050085531A1 (en) | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| AU2004282179B2 (en) | 2003-10-14 | 2011-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| WO2005035527A1 (en) | 2003-10-14 | 2005-04-21 | Pharmacia Corporation | Substituted pyrazinone compounds for the treatment of inflammation |
| WO2005040159A1 (en) | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| WO2005037797A1 (en) | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
| CA2542880A1 (en) | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
| BRPI0415678A (pt) | 2003-10-23 | 2006-12-19 | Pharmacia Corp | compostos de pirimidina para o tratamento de inflamação |
| WO2005044270A1 (en) | 2003-11-04 | 2005-05-19 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| WO2005051308A2 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc | Methods of treating diseases and disorders by targeting multiple kinases |
| FR2864084B1 (fr) | 2003-12-17 | 2006-02-10 | Aventis Pharma Sa | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| FR2876377B1 (fr) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| EP1896472A1 (de) | 2005-06-09 | 2008-03-12 | Boehringer Ingelheim International GmbH | Alpha-carboline als cdk-1 inhibitoren |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
-
2005
- 2005-10-14 AT AT05810353T patent/ATE479687T1/de not_active IP Right Cessation
- 2005-10-14 EP EP05810353.2A patent/EP1812439B2/en not_active Expired - Lifetime
- 2005-10-14 DE DE602005023333T patent/DE602005023333D1/de not_active Expired - Lifetime
- 2005-10-14 JP JP2007536949A patent/JP2008516973A/ja not_active Withdrawn
- 2005-10-14 WO PCT/US2005/037059 patent/WO2006044687A2/en not_active Ceased
- 2005-10-14 US US11/251,616 patent/US7713973B2/en active Active
-
2010
- 2010-04-06 US US12/755,301 patent/US8288536B2/en not_active Expired - Fee Related
-
2011
- 2011-12-26 JP JP2011284364A patent/JP5524171B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-17 JP JP2013006060A patent/JP2013121966A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516973A5 (https=) | ||
| JP6788649B2 (ja) | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 | |
| JP6858240B2 (ja) | Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物 | |
| JP5524171B2 (ja) | キナーゼ阻害剤 | |
| CN109311819B (zh) | 异喹啉-3-基甲酰胺类及其制备和其用途 | |
| CN1984914A (zh) | 7－氨基－3－苯基－二氢嘧啶并[4,5－d]嘧啶酮的酰胺衍生物、其制备和作为蛋白激酶抑制剂的应用 | |
| US20150315199A1 (en) | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders | |
| AU2004263277A1 (en) | 7-substituted 3-nitro-pyrazolo `1,5-a! pyrimidines |